Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment

Journal of Infectious Diseases

Volumn 192, Issue 5, 2005, Pages 720-727

  Shapiro, Roger L ^a,b   Holland, Diane T ^e   Capparelli, Edmund ^e   Lockman, Shahin ^a,c   Thior, Ibou ^a   Wester, Carolyn ^a   Stevens, Lisa ^a   Peter, Trevor ^a   Essex, Max ^a   Connor, James D ^e   Mirochnick, Mark ^d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; BOTSWANA; BREAST FEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MILK LEVEL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; INFANT; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; BOTSWANA; BREAST FEEDING; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; LACTATION; LAMIVUDINE; MILK, HUMAN; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; STATISTICS, NONPARAMETRIC; ZIDOVUDINE;

EID: 23944505278     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/432483     Document Type: Article

References (15)

1. The Breastfeeding and HIV International Transmission Study Group. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis 2004; 189:2154-66.
2. De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries. JAMA 2000; 283: 1175-82.
3. World Health Organization (WHO), WHO Collaborative Study Team. Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis. Lancet 2000; 355:451-55.
4. Vyankandondera J, Luchters S, Hassink E, et al. Reducing risk of HIV-1 transmission from mother to infant through breastfeeding using antiretroviral prophylaxis in infants (SIMBA study) [abstract LB7]. In: Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment (Paris). Geneva, International AIDS Society, 2003.
5. Gaillard P, Fowler MG, Dabis F, et al. Use of antiretroviral drugs to prevent HIV-1 transmission through breast-feeding: from animal studies to randomized clinical trials. J Acquir Immune Defic Syndr 2004; 35: 178-87.
6. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999; 13:479-86.
7. Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48:437-43.
8. Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. J Infect Dis 1998; 178:368-74.
9. GlaxoSmithKHne. Epivir (lamivudine) package insert. Research Triangle Park, NC: GlaxoSmithKline, 2002.
10. Guay L, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802.
11. Ruprecht RM, Sharpe AH, Jaenisch R, Trites D. Analysis of 3-azido-3-deoxythymidine levels in tissues and milk by isocratic high-performance liquid chromatography. J Chromatogr 1990; 528:371-83.
12. Acosta EP, King JR. Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus. Clin Infect Dis 2003; 36:373-7.
13. Hosseinipour M, Corbett A, Kanyama C, Mshali I, et al. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine, and nevirapine in 12 HIV-infected Malawian Subjects [abstract 631.]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005:288.
14. Aweeka F, Lizak P, Frenkel L, et al. Steady state nevirapine pharmacokinetics during second and third trimester pregnancy and postpartum: PACTG 1022 [abstract 932]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2004.
15. Wolf E, Ruemmelein N, Hoffmann C, et al. Week 2-nevirapine (NVP) plasma levels are associated with NVP-related toxicity [abstract TuPeB4640]. In: Program and abstracts of the XV International AIDS Conference (Bangkok). Geneva: International AIDS Society, 2004.